When the FDA approved a new treatment for some hemophilia patients, including those (like me) with Factor XI deficiency, a few people asked what that would mean for me. I emailed Carolyn Francis, the hemophilia coordinator at Georgetown University Hospital, to find out, and her response was – “it’s complicated.” Here’s the story, as sI understand it.